|
|
News Breaks
|
October 28, 2011
|
| 05:47 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharma reports promising data with TH-302 in soft tissue sarcoma | | Threshold Pharmaceuticals announced clinical trial results related to Threshold's Phase 3 clinical stage hypoxia-activated prodrug, TH-302. This single arm study investigated TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. The Phase 2 component of the multi-center trial enrolled patients with metastatic or locally advanced unresectable soft tissue sarcoma who have not previously received chemotherapy outside of the adjuvant or neoadjuvant setting. All patients were treated at the TH-302 maximum tolerated dose, or MTD, of 300 mg/m2 in combination with 75 mg/m2 doxorubicin. The results were presented at the Connective Tissue Oncology Society, or CTOS, Meeting in Chicago. :theflyonthewall.com |
|
|
News For THLD From The Last 14 Days Check below for free stories on THLD the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 25, 2012
|
| 07:36 EDT |  | THLD |
| theflyonthewall.com: | Threshold Pharmaceuticals remains undervalued, says Cowen | | Cowen said Threshold Pharmaceuticals remains undervalued in relation the potential of it's TH-302 drug for pancreatic cancer. The firm noted positive Phasellb results and estimates the sales potential in the U.S. alone at $1.5B+. Shares are Outperform rated. :theflyonthewall.com |
|
|
|
|
|
